What You Should Know:
– Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40M in Series A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, LifeX Ventures, and others.
– The funding will be used to accelerate the clinical validation and commercialization of its platform for chronic disease monitoring.
Molecular Blueprint for Chronic Disease
Curve Biosciences is addressing the rising costs and increasing prevalence of chronic diseases, asserting that improvements in patient monitoring are necessary to realize the full positive impact of modern breakthroughs, such as GLP-1s.
The company has developed the Whole-Body Atlas™, which is described as the world’s largest collection of manually curated tissue samples characterized by organ and disease state. By returning to this tissue-level biological truth, Curve is creating Whole-Body Blood Tests™.
These tests, powered by the company’s Whole-Body Intelligence platform, anticipate chronic disease, guide treatment decisions, and align stakeholders including patients, insurers, pharma, and doctors.
“To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests,” said Ritish Patnaik, PhD, CEO and Co-Founder of Curve Biosciences.
Executive Leadership and Clinical Actionability
The company has assembled a highly experienced executive team with deep expertise in developing advanced blood tests and precision medicine solutions:
- Ritish Patnaik, PhD, CEO: Former business development at Genentech, specializing in AI, data engineering, and precision testing.
- Nathan Hunkapiller, PhD, Chief Scientific Officer: Previously Head of R&D at Natera and GRAIL, where he led the development of advanced blood tests for oncology and prenatal screening.
- Alice Chen, PhD, Chief Operating Officer: Former Head of Product and Program Management at GRAIL, where she led strategy for a multi-cancer early detection blood test.
- Chuba Oyolu, PhD, Chief Technology Officer: Founding Scientist and Senior Site Director at Counsyl, with expertise in scaling advanced blood tests.
- Prof. Shan Wang, PhD, Chief Innovation Officer: Leland T. Edwards Professor at Stanford University, contributing over 300 publications and 70+ patents.
